Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue
ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (NASDAQ:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its entry into a research agreement expanding the study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons.
Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, “The initial three-month pilot study of SPU-21 assessed the peptide in healthy human and RA synovial tissue. The next step is to further investigate cyclic peptides in human tissue assays for optimization and binding affinity.”
Silo Pharma is advancing the development of SPU-21 liposomal joint homing peptides in collaboration with the University of Maryland, Baltimore (UMB).
